Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    21247627 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Condition: Breast Neoplasms
Interventions: Drug: exemestane (Aromasin);   Drug: tamoxifen + exemestane
2 Completed Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: exemestane;   Drug: tamoxifen
3 Completed Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: exemestane;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy

Indicates status has not been verified in more than two years